These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10743984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
    Feagan BG.
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 7. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC, Davis CW.
    Am J Health Syst Pharm; 2000 Nov 15; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP, Matchar DB, Harnett J, Wilson J.
    Chest; 2005 Nov 15; 128(5):3246-54. PubMed ID: 16304269
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb 15; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S.
    Curr Med Res Opin; 2005 Feb 15; 21(2):261-70. PubMed ID: 15801997
    [Abstract] [Full Text] [Related]

  • 17. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
    Marrie TJ.
    Chemotherapy; 2004 Feb 15; 50 Suppl 1():11-5. PubMed ID: 15319549
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
    Carratalà J, Fernández-Sabé N, Ortega L, Castellsagué X, Rosón B, Dorca J, Fernández-Agüera A, Verdaguer R, Martínez J, Manresa F, Gudiol F.
    Ann Intern Med; 2005 Feb 01; 142(3):165-72. PubMed ID: 15684204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.